Episodes
Friday Jul 28, 2023
Friday Jul 28, 2023
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines were recently updated with a focus on kidney health in patients with diabetes. The updated guidelines include recommendations on screening, prevention, and treatment of chronic kidney disease (CKD), including the use of SGLT2 inhibitors, finerenone, and ACE inhibitors or ARBs. The written commentary posted on the iForumRx website provides a succinct summary of the Top Ten Things Every Clinician Should Know.
Guest Authors: Kara Olstad, PharmD; Gurminder Sanghera, BSc, PharmD; and Darren Grabe, PharmD
Music by Good Talk
Thursday Oct 13, 2022
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
Thursday Oct 13, 2022
Thursday Oct 13, 2022
The 2022 AHA/ACC/HFSA Heart Failure Guidelines is a much-needed update and consolidates previously published recommendations. In the written commentary we describe the top ten things every clinician should know about the 2022 AHA/ACC/HFSA Heart Failure Guidelines. This podcast episode highlights some of the key recommendations from the guidelines and addresses some of the practical implications.
Guest Authors: Madison Yates, PharmD and Megan Supple, PharmD, BCACP, CPP
Music by Good Talk
Monday Jun 10, 2019
If Your Heart’s Not into It, Do You Really Need to Take Your Meds?
Monday Jun 10, 2019
Monday Jun 10, 2019
Dilated cardiomyopathy is the leading cause of sudden cardiac death and heart failure (HF) and the chief indication for cardiac transplantation. However, approximately 40% of patients see a significant improvement in left ventricular ejection fraction and reduction in the left ventricle size over time with pharmacologic treatment. As deprescribing becomes an increasingly important part of our clinical practice, we need more data about how deprescribing impacts outcomes, particularly in chronic diseases such as heart failure. The recently published TRED-HF is attempted to address this important question: Is the burden of lifelong therapy with medications necessary or worth it in patients with "recovered" dilated cardiomyopathy?
Guest Author: Jennifer Pruskowski, PharmD, BCPS, BCGP, CPE
Music by Good Talk
Friday Feb 24, 2017
Friday Feb 24, 2017
Hypertension affects more than 70% of patients with type 2 diabetes mellitus and further increases the risk of cardiovascular disease in this high-risk population. While renin angiotensin system (RAS) blockers are clearly indicated in patients with heart failure, chronic kidney disease with proteinuria, and coronary artery disease (CAD), experts have come to different conclusions regarding their role as initial antihypertensive therapy for patients with diabetes.
Theme Music by Good Talk
Friday Nov 11, 2016
Friday Nov 11, 2016
Approximately one in three patients with diabetes in the United States have chronic kidney disease (CKD). The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, published in 2015, demonstrated a reduction in cardiovascular and all-cause mortality in patients treated with empagliflozin. More recent data from the EMPA-REG OUTCOME trial suggests that empagliflozin may also confer significant renal protection.
Sunday May 17, 2015
Co-trimoxazole+RAAS Inhibitors: A Deadly Combination?
Sunday May 17, 2015
Sunday May 17, 2015
Could a commonly prescribed antibiotic, when combined with a renin-angiotensin system inhibitor, lead to sudden death?